Archives
-
IL-7, Human Recombinant: Assay Design Guide
2026-10-02
Learn how IL-7, human recombinant supports controlled immune-cell assays and how SARS-CoV-2 PLpro biology informs experimental controls. This guide connects cytokine assay design with ER-associated protein regulation while clearly separating evidence from hypothesis.
-
Hexa-Acylated LPS and Cancer Immunotherapy
2026-10-01
The reference study shows that the functional structure of gut microbiota-derived lipopolysaccharide, rather than the presence of LPS-producing taxa alone, can shape response to anti-PD-1 therapy. By integrating faecal metagenomics with human and mouse experiments, the authors identify hexa-acylated LPS as a TLR4-dependent enhancer of antitumour immunity and a potential biomarker of immunotherapy response.
-
Recombinant Human IL-6: A Mechanistic Assay Guide
2026-10-01
Recombinant Human IL-6, Tag Free can help researchers test cytokine responsiveness without introducing a fusion-tag variable. This guide connects IL-6 assay design with new evidence linking WDR36, glycolysis, and trophectoderm differentiation in human blastoid models.
-
Promethazine HCl: Macrophage Assay Workflows
2026-09-30
Promethazine HCl supports mechanism-focused studies that connect H1 receptor antagonism with macrophage ROS, lysosomal activity, and autophagy. This guide translates the phenothiazine literature into practical cell-assay workflows, controls, troubleshooting steps, and research-use boundaries.
-
Charge-Switching Lipids Reduce LNP Toxicity
2026-09-30
The reference study introduces switchable ionizable lipids that alter their charge between extracellular and endosomal pH, enabling efficient nucleic acid delivery while reducing several inflammatory pathways associated with conventional lipid nanoparticles. Its findings suggest that charge-state engineering can help separate endosomal escape from systemic inflammatory toxicity, including in a model of lipopolysaccharide-induced acute lung injury.
-
NF 340: Reading P2Y11 Signaling in Cancer
2026-09-29
NF 340 is a selective P2Y11 antagonist for dissecting purinergic signaling rather than merely suppressing a phenotype. This article connects the QPRT–myosin light-chain study to rigorous pathway attribution, assay interpretation, and responsible translation into immunology research.
-
Recombinant Human IL-6 in Blastoid Assays
2026-09-29
Use tag-free human IL-6 as a controlled cytokine variable in pluripotent stem cell and blastoid workflows, while keeping WDR36-linked metabolic findings analytically separate. This guide combines dose planning, time-course design, tag-related controls, and troubleshooting for exploratory lineage and metabolism studies.
-
NBC19 for Reproducible NLRP3 Assays
2026-09-28
Learn how NBC19 (SKU BA6129) can help researchers distinguish NLRP3-dependent IL-1β signaling from cell viability and cytotoxicity effects. This scenario-based guide covers THP1 assay design, dosing, controls, data interpretation, and practical product selection.
-
Anti-CD4 Antibody (Ibalizumab): Mechanism & Use
2026-09-28
Anti-CD4 Antibody (Ibalizumab) is the listed name for APExBIO catalog item F1001, but the available product dossier does not specify its formulation or research-use parameters. Ibalizumab’s established therapeutic mechanism is inhibition of HIV-1 entry after viral attachment; it is distinct from the CAR-macrophage strategy described in the cited hepatocellular carcinoma study.
-
Promethazine HCl: Macrophage Assay Workflows
2026-09-27
Use Promethazine HCl to probe histamine H1 signaling alongside macrophage ROS, autophagy, and antibacterial readouts. This practical guide separates literature findings from suggested pilot conditions so you can build a reproducible workflow without assuming that every phenothiazine shares the same mechanism.
-
Anlotinib Hydrochloride: Assay Workflows
2026-09-26
Build a mechanism-linked angiogenesis workflow with Anlotinib hydrochloride, from receptor phosphorylation and ERK readouts to endothelial migration and tube formation. The guide separates literature findings from practical starting conditions so researchers can distinguish target engagement from cell stress and direct tumor-cell effects.
-
Nitric Oxide Coordinates Aluminum Defense in Arabidopsis
2026-09-25
Xie et al. show that nitric oxide modifies STOP1 and STAR1 through S-nitrosylation in opposite ways, balancing external and internal aluminum detoxification in Arabidopsis. The findings connect a molybdenum-cofactor biosynthesis mutant to altered protein stability and offer a framework for studying how plants coordinate complementary stress-response pathways.
-
Ruxolitinib Rewires Mitochondrial Death in ATC
2026-09-25
A 2024 study links JAK1/2–STAT3 activity to DRP1-dependent mitochondrial fission in anaplastic thyroid carcinoma (ATC), and reports that ruxolitinib suppresses this pathway while inducing apoptosis and GSDME-associated pyroptosis. The findings establish a mechanistic rationale for further preclinical work, not evidence of clinical efficacy in ATC.
-
TAK-242 (Resatorvid) in TLR4 Autophagy Assays
2026-09-24
Use TAK-242 to test whether TLR4 contributes to parasite protein–induced macrophage autophagy, while separating receptor-dependent effects from vehicle, endotoxin, and cell-death artifacts. This workflow pairs a practical dose-finding plan with orthogonal pathway controls and clearly distinguishes proposed assay starting points from findings reported in the literature.
-
P2Y11 Antagonist NF 340 in Cell Invasion Studies
2026-09-24
Use NF 340 to test whether P2Y11 signaling contributes to QPRT-associated breast cancer cell migration, invasion, and myosin light-chain phosphorylation. This workflow pairs receptor pharmacology with pathway readouts and orthogonal controls, while keeping suggested assay settings distinct from conditions reported in the literature.